138 related articles for article (PubMed ID: 21694533)
1. Leukocytapheresis in pediatric patients with ulcerative colitis.
Tomomasa T; Tajiri H; Kagimoto S; Shimizu T; Yoden A; Ushijima K; Uchida K; Kaneko H; Abukawa D; Konno M; Maisawa S; Kohsaka T; Kobayashi A;
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):34-9. PubMed ID: 21694533
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Matsumoto T; Andoh A; Okawa K; Ito H; Torii A; Yoshikawa S; Nakaoka R; Okuyama Y; Oshitani N; Nishishita M; Watanabe K; Fukunaga K; Ohnishi K; Kusaka T; Yokoyama Y; Sasaki M; Tsujikawa T; Aoki T; Kusaka T; Takeda Y; Umehara Y; Nakamura S; Fujiyama Y
Ther Apher Dial; 2008 Dec; 12(6):484-90. PubMed ID: 19140847
[TBL] [Abstract][Full Text] [Related]
4. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy.
Nishioka C; Aoyama N; Maekawa S; Shirasaka D; Nakahara T; Tamura T; Fukagawa M; Umezu M; Abe T; Kasuga M
J Gastroenterol Hepatol; 2005 Oct; 20(10):1567-71. PubMed ID: 16174075
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of five days of consecutive leukocytapheresis for the treatment of ulcerative colitis: a preliminary study.
Tsujikawa T; Andoh A; Ogaẃa A; Sonoda A; Yagi Y; Hata K; Sasaki M; Saito Y; Fujiyama Y
Ther Apher Dial; 2009 Feb; 13(1):14-8. PubMed ID: 19379165
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis.
Shimada M; Iwase H; Tsuzuki T; Hirashima N; Kobayashi K; Hibino Y; Watanabe H; Ryuge N; Ando T; Goto H; Yagi Y; Tsujikawa T; Andoh A
Ther Apher Dial; 2008 Oct; 12(5):368-73. PubMed ID: 18937719
[TBL] [Abstract][Full Text] [Related]
7. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T
J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887
[TBL] [Abstract][Full Text] [Related]
8. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Sawada K; Kusugami K; Suzuki Y; Bamba T; Munakata A; Hibi T; Shimoyama T
Am J Gastroenterol; 2005 Jun; 100(6):1362-9. PubMed ID: 15929771
[TBL] [Abstract][Full Text] [Related]
9. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Ashida T; Kohgo Y; Munakata A; Noguchi M; Iizuka B; Endo Y; Hanai H; Yoshikawa T; Matsumoto T; Aoyama N; Matsui T; Mitsuyama K; Hibi T
Transfus Apher Sci; 2011 Apr; 44(2):113-7. PubMed ID: 21402309
[TBL] [Abstract][Full Text] [Related]
10. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients.
Nagayama K; Takedatsu H; Mitsuyama K; Yamasaki H; Kuwaki K; Yoshioka S; Kobayashi T; Yamauchi R; Kakuma T; Sata M
Ther Apher Dial; 2014 Jun; 18(3):244-51. PubMed ID: 24965290
[TBL] [Abstract][Full Text] [Related]
11. Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis?
Jo Y; Matsumoto T; Mibu R; Iida M
Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S3-9. PubMed ID: 14530652
[TBL] [Abstract][Full Text] [Related]
12. [Leukocytapheresis for ulcerative colitis].
Fukunaga K; Sawada K; Chikano S; Ohnishi K; Egashira A; Tanaka J; Nagase K; Satomi M; Shimoyama T
Nihon Rinsho; 1999 Nov; 57(11):2496-502. PubMed ID: 10572419
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis.
Nakano R; Iwakiri R; Ikeda Y; Kishi T; Tsuruoka N; Shimoda R; Sakata Y; Yamaguchi K; Fujimoto K
J Gastroenterol Hepatol; 2013 Feb; 28(2):303-8. PubMed ID: 23339387
[TBL] [Abstract][Full Text] [Related]
14. Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis.
Okuyama Y; Andoh A; Nishishita M; Fukunaga K; Kamikozuru K; Yokoyama Y; Ueno Y; Tanaka S; Kuge H; Yoshikawa S; Sugahara A; Anami E; Munetomo Y; Watanabe C; Fujiyama Y; Matsumoto T
Scand J Gastroenterol; 2013 Apr; 48(4):412-8. PubMed ID: 23356660
[TBL] [Abstract][Full Text] [Related]
15. [Leukocytapheresis for ulcerative colitis].
Sawada K; Ohnishi K; Kosaka T; Egashira A; Yamamura M; Satomi M; Shimoyama T
Nihon Geka Gakkai Zasshi; 1997 Apr; 98(4):438-42. PubMed ID: 9168498
[TBL] [Abstract][Full Text] [Related]
16. Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics.
Miyamoto H; Okahisa T; Iwaki H; Murata M; Ito S; Nitta Y; Akutagawa M; Kinouchi Y; Ohnishi Y; Oto J; Nishimura M
Ther Apher Dial; 2007 Feb; 11(1):16-21. PubMed ID: 17309570
[TBL] [Abstract][Full Text] [Related]
17. Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration.
Okada H; Takenaka R; Hiraoka S; Makidono C; Hori S; Kato J; Okazaki H; Kawamoto H; Mizuno M; Shiratori Y
Ther Apher Dial; 2006 Jun; 10(3):242-6. PubMed ID: 16817788
[TBL] [Abstract][Full Text] [Related]
18. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Ashizuka S; Nishiura R; Ishikawa N; Yamaga J; Inatsu H; Fujimoto S; Eto T
Ther Apher Dial; 2006 Feb; 10(1):54-8. PubMed ID: 16556137
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ulcerative colitis patients treated with leukocytapheresis and ulcerative colitis-associated colorectal cancer.
Kinugasa T; Akagi Y; Murotani K; Romeo K; Yoshida T; Ryu Y; Shiratuchi I; Shirouzu K
Anticancer Res; 2011 Jul; 31(7):2547-52. PubMed ID: 21873173
[TBL] [Abstract][Full Text] [Related]
20. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
Andoh A; Ogawa A; Kitamura K; Inatomi O; Fujino S; Tsujikawa T; Sasaki M; Mitsuyama K; Fujiyama Y
J Gastroenterol; 2004 Dec; 39(12):1150-7. PubMed ID: 15622478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
